来自于美国得克萨斯大学的James Grotta教授刊文报道说,SAINT-Ⅰ(急性缺血性卒中NXY治疗)研究表明,Ⅲ期试验显示阳性的首个神经保护剂可显著减轻缺血性卒中后患者的残疾状态。该项研究共包括1699例急性缺血性卒中发作6小时内被随机指定接受NXY-059输注72小时或安慰剂的患者；主要终点是在90天时通过Rankin评分检测患者的残疾程度；0为无残留性残疾,5为卧床并需长期护理。研究结果显示90天时,治疗组患者的残疾显著减轻；但两组的死亡率、严重和非严重不良事件率 Professor James Grotta from the University of Texas, USA, reported that the SAINT-Ⅰ (NXY treatment of acute ischemic stroke) study showed that the phase Ⅲ trial showed that the first positive neuroprotective agent significantly attenuated ischemic stroke patients Disability status. The study included 1699 patients randomized to either NXY-059 infusions for 72 hours or placebo within 6 hours of onset of acute ischemic stroke; the primary endpoint was the level of disability assessed by the Rankin score at 90 days; 0 was No residual disability, 5 bed and long-term care. The study showed significant reductions in disability in the treatment group at 90 days; however, mortality, rates of serious and non-serious adverse events